Psychiatry and Clinical Psychopharmacology
August 12, 2026
Doğa Sevinçok, Hasan Can Özbay, Mutlu Muhammed Özbek
Background: Functional somatic symptoms are common in children and adolescents and are often associated with anxiety and perceived stress. Mindfulness may be protective, but the mechanisms linking mindfulness to somatic symptom severity remain unclear. This study aimed to examine relationships between mindfulness, perceived stress, anxiety, and somatic symptom severity using a serial mediation...
Psychiatry and Clinical Psychopharmacology
March 30, 2026
Kenji Hashimoto, Feyza Arıcıoğlu, Mesut Çetin
Major depressive disorder remains a leading cause of disability worldwide, and current antidepressants are limited by delayed onset and incomplete response. Building on advances driven by ketamine research, renewed interest has focused on classical serotonergic psychedelics—particularly psilocybin, N,N-dimethyltryptamine (DMT), 5-methoxy-DMT, and lysergic acid diethylamide (LSD)—which, under...
Psychiatry and Clinical Psychopharmacology
November 13, 2025
Yu-Chih Shen, Chien-Chen Hung
This case report describes the clinical response and safety of intranasal esketamine (Spravato®) in a 61-year-old female with treatment-resistant depression (TRD), a history of electroconvulsive therapy (ECT) poor response, and structural brain abnormalities secondary to left frontal lobe tissue loss from traumatic brain injury in 2008. Despite multiple antidepressant trials, atypical...
Psychiatry and Clinical Psychopharmacology
August 14, 2025
Nadav Liam Modlin, Jessica L Maples-Keller, Maria Sarang et al.
Background: Current trauma treatment options often fail to meet patients' needs. Despite the availability of established interventions, many trauma treatments fail to adequately meet patients' needs. In parallel, there has been renewed scientific and public interest in the therapeutic potential of psychedelics and related compounds, accompanied by increasing unsupervised use. This underscores...
Psychiatry and Clinical Psychopharmacology
August 11, 2025
Reinhard Janssen-Aguilar, Shakila Meshkat, Huda Al-Shamali et al.
4 citations
Posttraumatic stress disorder (PTSD) is a severe, often difficult-to-treat condition, highlighting the need for innovative therapies. Interventional treatments, including neuromodulation, rapid-acting pharmacotherapies such as intravenous ketamine (IV-KET) and esketamine (ESK), and emerging psychedelic-assisted psychotherapies, offer promising solutions. This systematic review evaluates the...
Psychiatry and Clinical Psychopharmacology
August 11, 2025
Lisa Burback, Olga Winkler, Rakesh Jetly et al.
Traditional trauma-focused psychotherapies (TFPs) were developed based on an anxiety disorder model of posttraumatic stress disorder (PTSD). However, PTSD is a more complex disorder with heterogeneous onset, presentation, trajectory, and treatment responsivity. As half of treated patients do not respond to first-line treatments, innovative therapies are emerging to improve outcomes. This...
Psychiatry and Clinical Psychopharmacology
September 1, 2022
Mihriban Heval Özgen, W. van den Brink
In this case report, we present an adult male patient with autism spectrum disorder and a comorbid (treatment-resistant) mood disorder with suicidality. He has been treated with numerous psychopharmaceuticals, most recently risperidone and valproic acid. He has been hospitalized several times and has attempted suicide. He displayed limited social functioning, repetitive behaviors, sensory...